FI114097B - Trisyklisiä 5,6-dihydro-9H-pyratsolo[3,4-c]-1,2,4-triatsolo[4,3-alfa]pyridiinejä - Google Patents

Trisyklisiä 5,6-dihydro-9H-pyratsolo[3,4-c]-1,2,4-triatsolo[4,3-alfa]pyridiinejä Download PDF

Info

Publication number: FI114097B
Authority: FI; Finland
Prior art keywords: pyridine; pyrazolo; triazolo; ethyl; cyclopentyl
Prior art date: 1995-06-06

Application number

FI974434A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI974434A (fi

FI974434A0 (fi

Inventor

Kelvin Cooper

Allen Jacob Duplantier

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-06-06

Filing date

1997-12-05

Publication date

2004-08-13

1997-12-05 Application filed by Pfizer filed Critical Pfizer

1997-12-05 Publication of FI974434A publication Critical patent/FI974434A/fi

1997-12-05 Publication of FI974434A0 publication Critical patent/FI974434A0/fi

2004-08-13 Application granted granted Critical

2004-08-13 Publication of FI114097B publication Critical patent/FI114097B/fi

Links

201000004681 Psoriasis Diseases 0.000 title claims description 5
206010003246 arthritis Diseases 0.000 title claims description 5
208000006673 asthma Diseases 0.000 title claims description 5
206010006451 bronchitis Diseases 0.000 title claims description 4
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title description 4
239000003112 inhibitor Substances 0.000 title description 3
101710111837 Cyclic phosphodiesterase Proteins 0.000 title 1
102000018594 Tumour necrosis factor Human genes 0.000 title 1
108050007852 Tumour necrosis factor Proteins 0.000 title 1
230000004968 inflammatory condition Effects 0.000 title 1
125000000217 alkyl group Chemical group 0.000 claims abstract description 22
150000003839 salts Chemical class 0.000 claims abstract description 11
125000003545 alkoxy group Chemical group 0.000 claims abstract description 7
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 5
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 4
IEEJXQNVBDRVOQ-UHFFFAOYSA-N 3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1,3,7,9,11-pentaene Chemical class C1=CC2=CN=NC2=C2N=NCN21 IEEJXQNVBDRVOQ-UHFFFAOYSA-N 0.000 claims abstract 3
150000001875 compounds Chemical class 0.000 claims description 59
JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Substances C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 44
-1 pyridine compound Chemical class 0.000 claims description 32
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 24
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 claims description 22
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 claims description 22
108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 16
102000003390 tumor necrosis factor Human genes 0.000 claims description 16
230000015572 biosynthetic process Effects 0.000 claims description 8
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
238000011282 treatment Methods 0.000 claims description 7
125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 6
201000010099 disease Diseases 0.000 claims description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 6
230000002401 inhibitory effect Effects 0.000 claims description 6
206010040047 Sepsis Diseases 0.000 claims description 5
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 5
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 4
206010012434 Dermatitis allergic Diseases 0.000 claims description 4
206010039085 Rhinitis allergic Diseases 0.000 claims description 4
201000010105 allergic rhinitis Diseases 0.000 claims description 4
201000008937 atopic dermatitis Diseases 0.000 claims description 4
208000010668 atopic eczema Diseases 0.000 claims description 4
239000003814 drug Substances 0.000 claims description 4
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
208000005156 Dehydration Diseases 0.000 claims description 3
239000000460 chlorine Substances 0.000 claims description 3
230000018044 dehydration Effects 0.000 claims description 3
238000006297 dehydration reaction Methods 0.000 claims description 3
239000003937 drug carrier Substances 0.000 claims description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
230000035939 shock Effects 0.000 claims description 3
125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
208000030507 AIDS Diseases 0.000 claims description 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
229910052801 chlorine Inorganic materials 0.000 claims description 2
230000000694 effects Effects 0.000 claims description 2
125000002541 furyl group Chemical group 0.000 claims description 2
229910052736 halogen Inorganic materials 0.000 claims description 2
150000002367 halogens Chemical class 0.000 claims description 2
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
125000003226 pyrazolyl group Chemical group 0.000 claims description 2
125000004076 pyridyl group Chemical group 0.000 claims description 2
125000001544 thienyl group Chemical group 0.000 claims description 2
206010061218 Inflammation Diseases 0.000 claims 2
230000004054 inflammatory process Effects 0.000 claims 2
125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 1
CZSOESDMMFWTJY-UHFFFAOYSA-N 12-cyclopentyl-10-ethyl-5-(2-iodophenyl)-3,4,6,11,12-pentazatricyclo[7.3.0.02,6]dodeca-1(9),2,4,10-tetraene Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)I)C=2C2=C1C(CC)=NN2C1CCCC1 CZSOESDMMFWTJY-UHFFFAOYSA-N 0.000 claims 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
AJOWVHDRHWCPEK-UHFFFAOYSA-N chembl376440 Chemical compound C1CN2C(C3=CSC=C3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 AJOWVHDRHWCPEK-UHFFFAOYSA-N 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
125000000753 cycloalkyl group Chemical group 0.000 abstract description 7
125000003342 alkenyl group Chemical group 0.000 abstract description 6
125000002252 acyl group Chemical group 0.000 abstract description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 abstract description 2
125000001475 halogen functional group Chemical group 0.000 abstract 3
125000004450 alkenylene group Chemical group 0.000 abstract 1
125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
125000003118 aryl group Chemical group 0.000 abstract 1
125000004104 aryloxy group Chemical group 0.000 abstract 1
125000000000 cycloalkoxy group Chemical group 0.000 abstract 1
125000000623 heterocyclic group Chemical group 0.000 abstract 1
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
238000006243 chemical reaction Methods 0.000 description 34
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
238000002360 preparation method Methods 0.000 description 22
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 20
OAKJQQAXSVQMHS-UHFFFAOYSA-N hydrazine Substances NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 17
239000000203 mixture Substances 0.000 description 17
239000000243 solution Substances 0.000 description 16
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
239000011541 reaction mixture Substances 0.000 description 12
238000010992 reflux Methods 0.000 description 12
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 11
210000004027 cell Anatomy 0.000 description 11
238000000034 method Methods 0.000 description 11
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
239000000010 aprotic solvent Substances 0.000 description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical group [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
229910052757 nitrogen Inorganic materials 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
239000007787 solid Substances 0.000 description 8
238000003756 stirring Methods 0.000 description 7
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
239000003480 eluent Substances 0.000 description 6
239000003880 polar aprotic solvent Substances 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
210000003979 eosinophil Anatomy 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
239000012528 membrane Substances 0.000 description 5
UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 5
239000011734 sodium Substances 0.000 description 5
241000282412 Homo Species 0.000 description 4
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical group [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
239000012267 brine Substances 0.000 description 4
239000000284 extract Substances 0.000 description 4
239000003586 protic polar solvent Substances 0.000 description 4
230000035484 reaction time Effects 0.000 description 4
229910052708 sodium Inorganic materials 0.000 description 4
229910052938 sodium sulfate Inorganic materials 0.000 description 4
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
235000011152 sodium sulphate Nutrition 0.000 description 4
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 4
239000003039 volatile agent Substances 0.000 description 4
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
FIWILGQIZHDAQG-UHFFFAOYSA-N NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F Chemical compound NC1=C(C(=O)NCC2=CC=C(C=C2)OCC(F)(F)F)C=C(C(=N1)N)N1N=C(N=C1)C1(CC1)C(F)(F)F FIWILGQIZHDAQG-UHFFFAOYSA-N 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
239000008280 blood Substances 0.000 description 3
238000004440 column chromatography Methods 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
229910052749 magnesium Inorganic materials 0.000 description 3
238000002844 melting Methods 0.000 description 3
230000008018 melting Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000725 suspension Substances 0.000 description 3
230000006433 tumor necrosis factor production Effects 0.000 description 3
FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 2
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
KNYHISBJRQVMAZ-UHFFFAOYSA-N 1h-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C=NNC2=C1 KNYHISBJRQVMAZ-UHFFFAOYSA-N 0.000 description 2
IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 2
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 2
239000007995 HEPES buffer Substances 0.000 description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
239000007990 PIPES buffer Substances 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
BIVUUOPIAYRCAP-UHFFFAOYSA-N aminoazanium;chloride Chemical compound Cl.NN BIVUUOPIAYRCAP-UHFFFAOYSA-N 0.000 description 2
RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
238000003556 assay Methods 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
229920001971 elastomer Polymers 0.000 description 2
239000002158 endotoxin Substances 0.000 description 2
239000000706 filtrate Substances 0.000 description 2
239000007789 gas Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
238000000099 in vitro assay Methods 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000010410 layer Substances 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
239000001630 malic acid Substances 0.000 description 2
235000011090 malic acid Nutrition 0.000 description 2
210000000440 neutrophil Anatomy 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
210000002460 smooth muscle Anatomy 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
235000010265 sodium sulphite Nutrition 0.000 description 2
239000002904 solvent Substances 0.000 description 2
238000010186 staining Methods 0.000 description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 1
CYNYIHKIEHGYOZ-UHFFFAOYSA-N 1-bromopropane Chemical compound CCCBr CYNYIHKIEHGYOZ-UHFFFAOYSA-N 0.000 description 1
QJLZPHIDOKBEGS-UHFFFAOYSA-N 1-cyclopentyl-3-ethyl-5,6-dihydro-4h-pyrazolo[3,4-c]pyridin-7-one Chemical compound C1CNC(=O)C2=C1C(CC)=NN2C1CCCC1 QJLZPHIDOKBEGS-UHFFFAOYSA-N 0.000 description 1
SWACGCLWAODPJN-UHFFFAOYSA-N 1-cyclopentyl-3-ethyl-7-methylsulfanyl-4,5-dihydropyrazolo[3,4-c]pyridine Chemical compound C1CN=C(SC)C2=C1C(CC)=NN2C1CCCC1 SWACGCLWAODPJN-UHFFFAOYSA-N 0.000 description 1
STPXIOFWKOIYHX-UHFFFAOYSA-N 1-methylcyclohexane-1-carbonyl chloride Chemical compound ClC(=O)C1(C)CCCCC1 STPXIOFWKOIYHX-UHFFFAOYSA-N 0.000 description 1
FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 description 1
125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 1
BFJMHTOBRRZELQ-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-c]pyridine Chemical compound N1=CC=C2C(I)=NNC2=C1 BFJMHTOBRRZELQ-UHFFFAOYSA-N 0.000 description 1
FTAHXMZRJCZXDL-UHFFFAOYSA-N 3-piperideine Chemical compound C1CC=CCN1 FTAHXMZRJCZXDL-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical group N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 1
XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 1
CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
AEOBEOJCBAYXBA-UHFFFAOYSA-N A2P5P Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1OP(O)(O)=O AEOBEOJCBAYXBA-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
BAIYDCLETZLHLQ-UHFFFAOYSA-N C1CN2C=NN=C2C2=C1C=NN2 Chemical class C1CN2C=NN=C2C2=C1C=NN2 BAIYDCLETZLHLQ-UHFFFAOYSA-N 0.000 description 1
PISKBBMPBXMWMB-UHFFFAOYSA-N CCC1=NN(C=2C=CC(F)=CC=2)C2=C1CCN1C2=NN=C1C1(C)CCCCC1 Chemical compound CCC1=NN(C=2C=CC(F)=CC=2)C2=C1CCN1C2=NN=C1C1(C)CCCCC1 PISKBBMPBXMWMB-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
239000005977 Ethylene Substances 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000012981 Hank's balanced salt solution Substances 0.000 description 1
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
229910002651 NO3 Inorganic materials 0.000 description 1
NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
206010040844 Skin exfoliation Diseases 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical class [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
101100054666 Streptomyces halstedii sch3 gene Proteins 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
UCKMPCXJQFINFW-UHFFFAOYSA-N Sulphide Chemical compound [S-2] UCKMPCXJQFINFW-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102100040247 Tumor necrosis factor Human genes 0.000 description 1
IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
VYTBPJNGNGMRFH-UHFFFAOYSA-N acetic acid;azane Chemical compound N.N.CC(O)=O.CC(O)=O.CC(O)=O.CC(O)=O VYTBPJNGNGMRFH-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
230000001464 adherent effect Effects 0.000 description 1
150000001350 alkyl halides Chemical class 0.000 description 1
230000001088 anti-asthma Effects 0.000 description 1
239000000924 antiasthmatic agent Substances 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
239000012131 assay buffer Substances 0.000 description 1
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000004305 biphenyl Substances 0.000 description 1
230000037396 body weight Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
RDHPKYGYEGBMSE-UHFFFAOYSA-N bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
229910002092 carbon dioxide Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
230000003197 catalytic effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
ITZXULOAYIAYNU-UHFFFAOYSA-N cerium(4+) Chemical compound [Ce+4] ITZXULOAYIAYNU-UHFFFAOYSA-N 0.000 description 1
230000008859 change Effects 0.000 description 1
239000003610 charcoal Substances 0.000 description 1
PHIVEUQACADDGU-UHFFFAOYSA-N chembl218103 Chemical compound C1CN(C(=NN=2)C(C)(C)C)C=2C2=C1C(CC)=NN2C1CCCC1 PHIVEUQACADDGU-UHFFFAOYSA-N 0.000 description 1
VFNVUSQFRKXKQI-UHFFFAOYSA-N chembl218221 Chemical compound C1CN2C(CCC)=NN=C2C2=C1C(CC)=NN2C1CCCC1 VFNVUSQFRKXKQI-UHFFFAOYSA-N 0.000 description 1
CEMQXLVYSIOKKQ-UHFFFAOYSA-N chembl218653 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)Cl)C=2C2=C1C(CC)=NN2C1CCCC1 CEMQXLVYSIOKKQ-UHFFFAOYSA-N 0.000 description 1
DICDEJDXIQKUPO-UHFFFAOYSA-N chembl219223 Chemical compound C1CN(C(=NN=2)C=3C(=CC=CC=3)C(F)(F)F)C=2C2=C1C(CC)=NN2C1CCCC1 DICDEJDXIQKUPO-UHFFFAOYSA-N 0.000 description 1
OTBUQMMSFVAASQ-UHFFFAOYSA-N chembl374995 Chemical compound C1CN2C(C3CCCC3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 OTBUQMMSFVAASQ-UHFFFAOYSA-N 0.000 description 1
SYLAYNHYQLQFKX-UHFFFAOYSA-N chembl425987 Chemical compound C1CN2C(CC=3C=CC=CC=3)=NN=C2C2=C1C(CC)=NN2C1CCCC1 SYLAYNHYQLQFKX-UHFFFAOYSA-N 0.000 description 1
238000010411 cooking Methods 0.000 description 1
239000012043 crude product Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
229940095074 cyclic amp Drugs 0.000 description 1
GONHTJWVIZVBOU-UHFFFAOYSA-N cyclopentylhydrazine;hydron;chloride Chemical compound Cl.NNC1CCCC1 GONHTJWVIZVBOU-UHFFFAOYSA-N 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000035618 desquamation Effects 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
238000002651 drug therapy Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000000174 gluconic acid Substances 0.000 description 1
235000012208 gluconic acid Nutrition 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000006289 hydroxybenzyl group Chemical group 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
239000008101 lactose Substances 0.000 description 1
GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
108010052968 leupeptin Proteins 0.000 description 1
238000012417 linear regression Methods 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
239000006210 lotion Substances 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
238000002826 magnetic-activated cell sorting Methods 0.000 description 1
MIKKOBKEXMRYFQ-WZTVWXICSA-N meglumine amidotrizoate Chemical compound C[NH2+]C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C([O-])=O)=C1I MIKKOBKEXMRYFQ-WZTVWXICSA-N 0.000 description 1
UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
AGJSNMGHAVDLRQ-HUUJSLGLSA-N methyl (2s)-2-[[(2r)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-HUUJSLGLSA-N 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
210000005087 mononuclear cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
229960000988 nystatin Drugs 0.000 description 1
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
239000002674 ointment Substances 0.000 description 1
239000012044 organic layer Substances 0.000 description 1
NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
239000008024 pharmaceutical diluent Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
239000013641 positive control Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
239000000047 product Substances 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
238000010926 purge Methods 0.000 description 1
KFUSANSHCADHNJ-UHFFFAOYSA-N pyridine-3-carbohydrazide Chemical compound NNC(=O)C1=CC=CN=C1 KFUSANSHCADHNJ-UHFFFAOYSA-N 0.000 description 1
150000003222 pyridines Chemical class 0.000 description 1
238000000611 regression analysis Methods 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
238000003345 scintillation counting Methods 0.000 description 1
239000012312 sodium hydride Substances 0.000 description 1
229910000104 sodium hydride Inorganic materials 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000001384 succinic acid Substances 0.000 description 1
235000011044 succinic acid Nutrition 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000004809 thin layer chromatography Methods 0.000 description 1
150000003571 thiolactams Chemical class 0.000 description 1
150000003573 thiols Chemical class 0.000 description 1
QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
238000000954 titration curve Methods 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
QIWRFOJWQSSRJZ-UHFFFAOYSA-N tributyl(ethenyl)stannane Chemical compound CCCC[Sn](CCCC)(CCCC)C=C QIWRFOJWQSSRJZ-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
230000035899 viability Effects 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
229920002554 vinyl polymer Polymers 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1
238000005406 washing Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Oncology (AREA)
Pulmonology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
AIDS & HIV (AREA)
Pain & Pain Management (AREA)
Molecular Biology (AREA)
Tropical Medicine & Parasitology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

FI974434A 1995-06-06 1997-12-05 Trisyklisiä 5,6-dihydro-9H-pyratsolo[3,4-c]-1,2,4-triatsolo[4,3-alfa]pyridiinejä FI114097B (fi)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
CA2223624		1995-06-06
CA002223624A CA2223624C (en)	1995-06-06	1995-06-06	Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-.alpha.]pyridines
IB9500429		1995-06-06
PCT/IB1995/000429 WO1996039408A1 (en)	1995-06-06	1995-06-06	TRICYCLIC 5,6-DIHYDRO-9H-PYRAZOLO[3,4-c]-1,2,4-TRIAZOLO[4,3-α]PYRIDINES
HU9601541A HUP9601541A3 (en)	1995-06-06	1996-06-05	Tricyclic 5,6-dihydro-9h-pyrazolo[3,4-c]-1,2,4-triazolol[4,3-a]-pyridines and pharmaceutical compositions containing them
HU9601541		1996-06-05

Publications (3)

Publication Number	Publication Date
FI974434A FI974434A (fi)	1997-12-05
FI974434A0 FI974434A0 (fi)	1997-12-05
FI114097B true FI114097B (fi)	2004-08-13

Family

ID=89994031

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI974434A FI114097B (fi)	1995-06-06	1997-12-05	Trisyklisiä 5,6-dihydro-9H-pyratsolo[3,4-c]-1,2,4-triatsolo[4,3-alfa]pyridiinejä

Country Status (43)

Country	Link
US (1)	US6004974A (ko)
EP (1)	EP0837860B1 (ko)
JP (1)	JP3107827B2 (ko)
KR (2)	KR100191972B1 (ko)
CN (1)	CN1061044C (ko)
AP (1)	AP609A (ko)
AR (1)	AR002745A1 (ko)
AT (1)	ATE214700T1 (ko)
AU (1)	AU694871B2 (ko)
BG (1)	BG62568B1 (ko)
BR (1)	BR9602627A (ko)
CA (1)	CA2223624C (ko)
CO (1)	CO4700460A1 (ko)
CZ (1)	CZ287251B6 (ko)
DE (1)	DE69525978T2 (ko)
DK (1)	DK0837860T3 (ko)
DZ (1)	DZ2044A1 (ko)
ES (1)	ES2172583T3 (ko)
FI (1)	FI114097B (ko)
HR (1)	HRP960268B1 (ko)
HU (1)	HUP9601541A3 (ko)
IL (1)	IL118485A (ko)
IS (1)	IS1913B (ko)
LV (1)	LV11620B (ko)
MA (1)	MA23893A1 (ko)
MX (1)	MX9709897A (ko)
MY (1)	MY116527A (ko)
NO (1)	NO306256B1 (ko)
NZ (1)	NZ286734A (ko)
OA (1)	OA10458A (ko)
PL (1)	PL184195B1 (ko)
PT (1)	PT837860E (ko)
RO (1)	RO115881B1 (ko)
RU (1)	RU2161158C2 (ko)
SA (1)	SA96170065B1 (ko)
SG (1)	SG54341A1 (ko)
SI (1)	SI9600186A (ko)
SK (1)	SK282167B6 (ko)
TN (1)	TNSN96083A1 (ko)
TR (1)	TR199600482A1 (ko)
TW (1)	TW460469B (ko)
WO (1)	WO1996039408A1 (ko)
YU (1)	YU49346B (ko)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2792938B1 (fr)	1999-04-28	2001-07-06	Warner Lambert Co	NOUVELLES 1-AMINO TRIAZOLO [4,3-a] QUINAZOLINE-5-ONES INHIBITRICES DE PHOSPHODIESTERASES IV
US6326495B2 (en) *	1999-04-30	2001-12-04	Pfizer Inc.	Process for preparing 8-cyclopentyl-6-ethyl-3-[substituted]-5,8-dihydro-4H-1,2,3a,7,8-pentaaza-as-indacenes and intermediates useful therein
EP1380585B1 (en) *	1999-04-30	2004-11-10	Pfizer Products Inc.	Pyrazolopyridinone as intermediate
CA2381802C (en)	1999-08-21	2010-12-07	Byk Gulden Lomberg Chemische Fabrik Gmbh	Synergistic combination of roflumilast and salmeterol
WO2001068600A2 (en) *	2000-03-16	2001-09-20	Inflazyme Pharmaceuticals Limited	Benzylated pde4 inhibitors
MXPA03010791A (es) *	2001-05-25	2004-03-02	Boehringer Ingelheim Pharma	Combinacion de inhibidor de pde4 y tiotropio a sus derivados para tratamiento de enfermedades obstructivas de vias respiratorias y de otras enfermedades inflamatorias.
JP2005508861A (ja) *	2001-05-25	2005-04-07	ファイザー・インク	閉塞性気管疾患の治療のためのｐｄｅ４阻害剤及び抗コリン性剤の組み合わせ物
GB0122031D0 (en) *	2001-09-12	2001-10-31	Pfizer Ltd	Use of pde4 inhibitors in a dry powder inhaler
GB0129395D0 (en) *	2001-12-07	2002-01-30	Pfizer Ltd	Pharmaceutical combination
US20050107420A1 (en) *	2002-05-23	2005-05-19	Boehringe Ingelheim Pharma Gmbh & Co. Kg	Combination of a PDE4 inhibitor and tiotropium or derivative thereof for treating obstructive airways and other inflammatory diseases
WO2006075748A1 (ja) *	2005-01-17	2006-07-20	Santen Pharmaceutical Co., Ltd.	アレルギー性結膜疾患治療剤
RU2008119323A (ru)	2005-10-19	2009-11-27	Рэнбакси Лабораториз Лимитед (In)	Фармацевтические композиции мускаринового рецептора
CN102764440A (zh)	2006-07-05	2012-11-07	奈科明有限责任公司	用于治疗炎症性肺部疾病的HMG-CoA还原酶抑制剂与磷酸二酯酶4抑制剂的组合
US8653097B2 (en) *	2008-10-17	2014-02-18	Boehringer Ingelheim International Gmbh	Tetra-aza-heterocycles as phosphatidylinositol-3-kinases (P13-kinases) inhibitor
JP5730896B2 (ja) *	2009-12-04	2015-06-10	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	トリシクロピラゾール誘導体
WO2013084182A1 (en)	2011-12-08	2013-06-13	Glenmark Pharmaceuticals S.A.	Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3697532A (en) *	1970-08-12	1972-10-10	Squibb & Sons Inc	5-methyldipyrazolo {8 3,4-b;3{40 ,4{40 -d{9 {0 pyridin-3(2h)-ones
HUT74170A (en) *	1993-07-06	1996-11-28	Pfizer	Bicyclic tetrahydro pyrazolopyridines
CA2143143A1 (en) *	1994-03-08	1995-09-09	Toshihiko Tanaka	3-phenylpyrrolidine derivatives

1995
- 1995-06-06 AT AT95918707T patent/ATE214700T1/de not_active IP Right Cessation
- 1995-06-06 MX MX9709897A patent/MX9709897A/es unknown
- 1995-06-06 EP EP95918707A patent/EP0837860B1/en not_active Expired - Lifetime
- 1995-06-06 CA CA002223624A patent/CA2223624C/en not_active Expired - Fee Related
- 1995-06-06 US US08/973,590 patent/US6004974A/en not_active Expired - Fee Related
- 1995-06-06 ES ES95918707T patent/ES2172583T3/es not_active Expired - Lifetime
- 1995-06-06 DE DE69525978T patent/DE69525978T2/de not_active Expired - Fee Related
- 1995-06-06 SK SK718-96A patent/SK282167B6/sk unknown
- 1995-06-06 JP JP08511176A patent/JP3107827B2/ja not_active Expired - Fee Related
- 1995-06-06 PT PT95918707T patent/PT837860E/pt unknown
- 1995-06-06 WO PCT/IB1995/000429 patent/WO1996039408A1/en active IP Right Grant
- 1995-06-06 DK DK95918707T patent/DK0837860T3/da active
1996
- 1996-05-02 TW TW085105271A patent/TW460469B/zh not_active IP Right Cessation
- 1996-05-06 AP APAP/P/1996/000806A patent/AP609A/en active
- 1996-05-20 AR ARP960102626A patent/AR002745A1/es unknown
- 1996-05-27 PL PL96314459A patent/PL184195B1/pl not_active IP Right Cessation
- 1996-05-30 IL IL11848596A patent/IL118485A/xx not_active IP Right Cessation
- 1996-06-03 IS IS4350A patent/IS1913B/is unknown
- 1996-06-04 LV LVP-96-174A patent/LV11620B/en unknown
- 1996-06-04 SA SA96170065A patent/SA96170065B1/ar unknown
- 1996-06-04 BR BR9602627A patent/BR9602627A/pt active Search and Examination
- 1996-06-05 BG BG100640A patent/BG62568B1/bg unknown
- 1996-06-05 KR KR1019960020169A patent/KR100191972B1/ko not_active IP Right Cessation
- 1996-06-05 HU HU9601541A patent/HUP9601541A3/hu unknown
- 1996-06-05 TN TNTNSN96083A patent/TNSN96083A1/fr unknown
- 1996-06-05 MA MA24263A patent/MA23893A1/fr unknown
- 1996-06-05 YU YU34696A patent/YU49346B/sh unknown
- 1996-06-05 NO NO962320A patent/NO306256B1/no unknown
- 1996-06-05 DZ DZ960088A patent/DZ2044A1/fr active
- 1996-06-05 RU RU96111027/04A patent/RU2161158C2/ru not_active IP Right Cessation
- 1996-06-05 CZ CZ19961626A patent/CZ287251B6/cs not_active IP Right Cessation
- 1996-06-05 MY MYPI96002201A patent/MY116527A/en unknown
- 1996-06-05 AU AU54773/96A patent/AU694871B2/en not_active Ceased
- 1996-06-05 SG SG1996009983A patent/SG54341A1/en unknown
- 1996-06-05 NZ NZ286734A patent/NZ286734A/en unknown
- 1996-06-06 HR HR960268A patent/HRP960268B1/xx not_active IP Right Cessation
- 1996-06-06 SI SI9600186A patent/SI9600186A/sl not_active IP Right Cessation
- 1996-06-06 OA OA60834A patent/OA10458A/en unknown
- 1996-06-06 TR TR96/00482A patent/TR199600482A1/xx unknown
- 1996-06-06 CO CO96029521A patent/CO4700460A1/es unknown
- 1996-06-06 CN CN96107630A patent/CN1061044C/zh not_active Expired - Fee Related
- 1996-06-06 RO RO96-01157A patent/RO115881B1/ro unknown
1997
- 1997-12-05 FI FI974434A patent/FI114097B/fi active
1998
- 1998-10-24 KR KR1019980044720A patent/KR100225719B1/ko not_active IP Right Cessation

Also Published As

Publication number	Publication date
FI974434A (fi)	1997-12-05
YU34696A (sh)	1999-07-28
CN1142499A (zh)	1997-02-12
JP3107827B2 (ja)	2000-11-13
TNSN96083A1 (fr)	2005-03-15
CO4700460A1 (es)	1998-12-29
NZ286734A (en)	1998-02-26
RU2161158C2 (ru)	2000-12-27
PT837860E (pt)	2002-07-31
SA96170065B1 (ar)	2005-12-21
NO306256B1 (no)	1999-10-11
HU9601541D0 (en)	1996-07-29
MX9709897A (es)	1998-03-31
CA2223624C (en)	2001-02-20
BR9602627A (pt)	1998-09-01
CN1061044C (zh)	2001-01-24
EP0837860B1 (en)	2002-03-20
BG62568B1 (bg)	2000-02-29
MY116527A (en)	2004-02-28
KR970003440A (ko)	1997-01-28
DZ2044A1 (fr)	2002-07-21
IL118485A0 (en)	1996-09-12
PL184195B1 (pl)	2002-09-30
CA2223624A1 (en)	1996-12-12
PL314459A1 (en)	1996-12-09
KR100191972B1 (ko)	1999-06-15
FI974434A0 (fi)	1997-12-05
JPH10510242A (ja)	1998-10-06
IS1913B (is)	2004-02-03
EP0837860A1 (en)	1998-04-29
HRP960268B1 (en)	2002-12-31
IS4350A (is)	1996-12-07
OA10458A (en)	2002-03-27
DK0837860T3 (da)	2002-05-27
SK282167B6 (sk)	2001-11-06
AU5477396A (en)	1996-12-19
HUP9601541A3 (en)	1997-05-28
KR100225719B1 (en)	1999-10-15
HUP9601541A2 (en)	1997-02-28
DE69525978D1 (de)	2002-04-25
LV11620B (en)	1997-04-20
ATE214700T1 (de)	2002-04-15
RO115881B1 (ro)	2000-07-28
NO962320L (no)	1996-12-09
ES2172583T3 (es)	2002-10-01
YU49346B (sh)	2005-07-19
LV11620A (lv)	1996-12-20
AU694871B2 (en)	1998-07-30
HRP960268A2 (en)	1997-08-31
AR002745A1 (es)	1998-04-29
WO1996039408A1 (en)	1996-12-12
CZ162696A3 (en)	1997-01-15
US6004974A (en)	1999-12-21
TR199600482A1 (tr)	1997-03-21
SI9600186A (en)	1997-04-30
SK71896A3 (en)	1997-05-07
DE69525978T2 (de)	2002-12-19
SG54341A1 (en)	1998-11-16
MA23893A1 (fr)	1996-12-31
NO962320D0 (no)	1996-06-05
AP609A (en)	1997-09-03
AP9600806A0 (en)	1996-07-31
IL118485A (en)	2000-02-17
CZ287251B6 (en)	2000-10-11
TW460469B (en)	2001-10-21
BG100640A (bg)	1997-03-31

Publication	Publication Date	Title
FI114097B (fi)	2004-08-13	Trisyklisiä 5,6-dihydro-9H-pyratsolo[3,4-c]-1,2,4-triatsolo[4,3-alfa]pyridiinejä
EP2598505B1 (en)	2015-03-18	Substituted imidazo[1,2-b]pyridazines
US8138193B2 (en)	2012-03-20	Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases
AU2007275816A1 (en)	2008-01-24	1-hydroxy naphthyridine compounds as anti-HIV agents
TW201136936A (en)	2011-11-01	Pyrrolopyrazine kinase inhibitors
TW200938547A (en)	2009-09-16	Pyrrolopyrazine kinase inhibitors
US8044065B2 (en)	2011-10-25	Benzothienopyridines for use as inhibitors of Eg5 kinesin
US6303613B1 (en)	2001-10-16	Aminopyrimidine derivatives, processes for their preparation, compositions containing them and their use as pharmaceuticals
CZ224897A3 (cs)	1998-04-15	Tricyklické diazepinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
US20090036482A1 (en)	2009-02-05	Imidazopyridine-derivatives as inductible no-synthase inhibitors
CA2540230A1 (en)	2005-07-07	Aminopyridine-derivatives as inductible no-synthase inhibitors
AP932A (en)	2001-02-02	Tricyclic 5,6-dihydro-9H-pyrazolo (3,4c)-1,2,4,-triazolo (4,3-a) pyridines.
TW202342013A (zh)	2023-11-01	雜環化合物、其組成物及用其進行治療之方法
TW201134826A (en)	2011-10-16	Pyrrolopyrazine kinase inhibitors
UA45961C2 (uk)	2002-05-15	ТРИЦИКЛІЧНІ 5,6-ДИГІДРО-9Н-ПІРАЗОЛО[3,4-с]-1,2,4-ТРИАЗОЛО[4,3-а]ПІРИДИНИ, СПОСІБ ІНГІБУВАННЯ ФОСФОДІЕСТЕРАЗИ (PDE) ТИПУ IV, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ